Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165217 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00165217 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 37 participants.
The verdict
NCT00165217, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.
Interventions
- DRUG Capecitabine
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165217
The ClinicalTrials.gov registry entry for NCT00165217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00165217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165217 about?
NCT00165217 is a clinical study titled "Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma". The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.
What is the current status of trial NCT00165217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2001-11. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00165217?
The interventions under investigation include: Capecitabine (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00165217?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.